Pathology & Laboratory Medicine

Publications

Filter By Faculty

Filter by Principal Investigator

2003

Yao DX, Hoda SA, Yin DY, Kuhel WI, Harigopal M, Resetkova E, et al. Interpretative problems and preparative technique influence reliability of intraoperative parathyroid touch imprints. Arch Pathol Lab Med. 2003;127(1):64-7.

Magro CM, Nuovo GJ, A Crowson N. The utility of the in situ detection of T-cell receptor Beta rearrangements in cutaneous T-cell-dominant infiltrates. Diagn Mol Pathol. 2003;12(3):133-41.

Lieberfarb ME, Lin M, Lechpammer M, Li C, Tanenbaum DM, Febbo PG, et al. Genome-wide loss of heterozygosity analysis from laser capture microdissected prostate cancer using single nucleotide polymorphic allele (SNP) arrays and a novel bioinformatics platform dChipSNP. Cancer Res. 2003;63(16):4781-5.

Fournier E, Isakoff SJ, Ko K, Cardinale CJ, Inghirami GG, Li Z, et al. The B cell SH2/PH domain-containing adaptor Bam32/DAPP1 is required for T cell-independent II antigen responses. Curr Biol. 2003;13(21):1858-66.

Watnick RS, Cheng Y-, Rangarajan A, Ince TA, Weinberg RA. Ras modulates Myc activity to repress thrombospondin-1 expression and increase tumor angiogenesis. Cancer Cell. 2003;3(3):219-31.

Lesinski GB, Anghelina M, Zimmerer J, Bakalakos T, Badgwell B, Parihar R, et al. The antitumor effects of IFN-alpha are abrogated in a STAT1-deficient mouse. J Clin Invest. 2003;112(2):170-80.

Leonard JP, Coleman M, Ketas JC, Chadburn A, Ely S, Furman RR, et al. Phase I/II trial of epratuzumab (humanized anti-CD22 antibody) in indolent non-Hodgkin's lymphoma. J Clin Oncol. 2003;21(16):3051-9.

Rand JH. The antiphospholipid syndrome. Annu Rev Med. 2003;54:409-24.

Chiarle R, Gong JZ, Guasparri I, Pesci A, Cai J, Liu J, et al. NPM-ALK transgenic mice spontaneously develop T-cell lymphomas and plasma cell tumors. Blood. 2003;101(5):1919-27.

Rossi S, Loda M. The role of the ubiquitination-proteasome pathway in breast cancer: use of mouse models for analyzing ubiquitination processes. Breast Cancer Res. 2003;5(1):16-22.